A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors

被引:34
作者
Blair, WS
Isaacson, J
Li, XQ
Cao, J
Peng, QH
Kong, GFZ
Patick, AK
机构
[1] Pfizer Global Res & Dev, Dept Virol, La Jolla Labs, San Diego, CA 92121 USA
[2] Pfizer Global Res & Dev, Dept Biostat & Reporting, La Jolla Labs, San Diego, CA 92121 USA
关键词
HIV; antiviral screen; reporter virus; cell-based assay;
D O I
10.1016/j.antiviral.2004.11.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antiviral high throughput screens remain a viable option for identifying novel target inhibitors. However, few antiviral screens have been reduced to practice on an industrial scale. In this study, we describe an HIV-1 dual reporter assay that allows for the simultaneous evaluation of the potential antiviral activities and cytotoxicities of compounds in a high throughput screen (HTS) format. We validate the assay with known HIV-1 inhibitors and show that the antiviral and cytotoxic activities of compounds are reproducibly measured under screening conditions. In addition, we show that the assay exhibits parameters (e.g., signal-to-background ratios and Z' coefficients) suitable for high throughout screening. In a pilot screen, we demonstrate that non-specific or cytotoxic compounds represent a significant fraction of the hits identified in an antiviral screen and that these false positives are identified and deprioritized by the HIV-1 dual reporter assay at the primary screening step. We propose that the HIV-1 dual reporter assay represents a novel approach to HIV-1 antiviral screening that allows for the effective execution of industrial scale HTS campaigns with significantly greater returns on resource investment when compared to previous methods. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:107 / 116
页数:10
相关论文
共 36 条
[1]   Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1 [J].
Adelson, ME ;
Pacchia, AL ;
Kaul, M ;
Rando, RF ;
Ron, Y ;
Peltz, SW ;
Dougherty, JP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :501-508
[2]   High-efficiency gene transfer into CD34(+) cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G [J].
Akkina, RK ;
Walton, RM ;
Chen, ML ;
Li, QX ;
Planelles, V ;
Chen, ISY .
JOURNAL OF VIROLOGY, 1996, 70 (04) :2581-2585
[3]  
Billington CK, 2003, RESP RES, V4
[4]  
BLAIR WS, 2004, Patent No. 2004048613
[5]  
BLAIR WS, 2001, Patent No. 0196610
[6]  
BLAIR WS, 2002, Patent No. 6469006
[7]  
BOYD MR, 1988, AIDS ETIOLOGY DIAGNO, P305
[8]   DISTINCT MODES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROVIRAL LATENCY REVEALED BY SUPERINFECTION OF NONPRODUCTIVELY INFECTED CELL-LINES WITH RECOMBINANT LUCIFERASE-ENCODING VIRUSES [J].
CHEN, BK ;
SAKSELA, K ;
ANDINO, R ;
BALTIMORE, D .
JOURNAL OF VIROLOGY, 1994, 68 (02) :654-660
[9]  
Dorsky DI, 1999, J ACQ IMMUN DEF SYND, V22, P213
[10]  
Fujita T, 1994, OLFACTION TASTE, Vxi, P2